Evidence map›Paper›PMID 26606676›Full record

ArticlePloS one2015

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.

Michishige Terasaki, Munenori Hiromura, Yusaku Mori, Kyoko Kohashi, Masaharu Nagashima, Hideki Kushima, Takuya Watanabe, Tsutomu Hirano

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05998525 (Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography), which is not on this map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05998525 phase3completedstarted 2021, after this paper: background citation

Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

Ran2021Enrolled54Registered outcomes6Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Diabete Type 2, Myocardial Infarction, Unstable AnginaArmsDapagliflozin 10mg Tab, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.American journal of preventive cardiology · 2025
    Review
  10. Review
  11. Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.International journal of molecular sciences · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Michishige TerasakiDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Munenori HiromuraDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Yusaku MoriDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Kyoko KohashiDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Masaharu NagashimaDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Hideki KushimaDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Takuya WatanabeLaboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji-City, Tokyo, Japan.
Tsutomu HiranoDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo, Japan.
Showa University · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct associations between hyperglycemia and atherosclerosis remain unclear. We investigated the association between the amelioration of glycemia by sodium-glucose cotransporter 2 inhibitors (SGLT2is) and macrophage-driven atherosclerosis in diabetic mice. We administered dapagliflozin or ipragliflozin (1.0 mg/kg/day) for 4-weeks to apolipoprotein E-null (Apoe-/-) mice, streptozotocin-induced diabetic Apoe-/- mice, and diabetic db/db mice. We then determined aortic atherosclerosis, oxidized low-density lipoprotein (LDL)-induced foam cell formation, and related gene expression in exudate peritoneal macrophages. Dapagliflozin substantially decreased glycated hemoglobin (HbA1c) and glucose tolerance without affecting body weight, blood pressure, plasma insulin, and lipids in diabetic Apoe-/- mice. Aortic atherosclerotic lesions, atheromatous plaque size, and macrophage infiltration in the aortic root increased in diabetic Apoe-/- mice; dapagliflozin attenuated these changes by 33%, 27%, and 20%, respectively. Atherosclerotic lesions or foam cell formation highly correlated with HbA1c. Dapagliflozin did not affect atherosclerosis or plasma parameters in non-diabetic Apoe-/- mice. In db/db mice, foam cell formation increased by 4-fold compared with C57/BL6 mice, whereas ipragliflozin decreased it by 31%. Foam cell formation exhibited a strong correlation with HbA1c. Gene expression of lectin-like ox-LDL receptor-1 and acyl-coenzyme A:cholesterol acyltransferase 1 was upregulated, whereas that of ATP-binding cassette transporter A1 was downregulated in the peritoneal macrophages of both types of diabetic mice. SGLT2i normalized these gene expressions. Our study is the first to demonstrate that SGLT2i exerts anti-atherogenic effects by pure glucose lowering independent of insulin action in diabetic mice through suppressing macrophage foam cell formation, suggesting that foam cell formation is highly sensitive to glycemia ex vivo.

Indexed as

Diabetes Mellitus, ExperimentalSodium-Glucose Transporter 2 InhibitorsAnimalsAtherosclerosisBenzhydryl CompoundsBlood GlucoseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease Models, AnimalFoam CellsGene ExpressionGlucose Tolerance TestGlucosidesHyperglycemiaHypoglycemic AgentsMacrophages, PeritonealBenzhydryl CompoundsBlood GlucosedapagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID26606676
PMCPMC4659635
OpenAlexW2175231274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.